Health Care Pulls Back as Investors Rotate Into Growth Stocks

Companies graded A or B make up 51.2% of the Health Care sector, but quality alone did not prevent a decline on Monday, October 19. The exchange-traded fund Health Care Select Sector SPDR Fund (XLV) closed -0.6% as participation remained narrow, with 41.7% of sector members advancing. Heavyweight holdings accounted for most of that pressure: the cap-weighted sector finished -0.6%, while an equal-weighted version was -0.3%. The weakness stemmed from a broader market rotation where technology and artificial intelligence shares rallied while most other industry groups fell. That momentum prompted investors to rotate capital into growth names.

That broader rotation overshadowed positive sentiment that has built around health care in recent weeks. The sector has drawn steady inflows tied to defensive positioning and expectations surrounding upcoming midterm elections. Despite Monday's retreat, XLV stands +4.3% over the past month. The session functioned as a pause in that trend rather than a structural shift.

Inside the sector, clinical updates created sharp divergences among individual components. Moderna Inc led gainers, closing +4.1% as analysts raised price targets ahead of mid-stage melanoma trial results. Large pharmaceuticals also released encouraging pipeline updates. AbbVie shared favorable mid-stage clinical data for a Crohn's disease treatment. Meanwhile, Johnson & Johnson reported 48-week results showing sustained remission in Crohn's patients for its therapy Tremfya. On the downside, Henry Schein Inc closed -2.8%, though our sources show no reported driver for the move.

As an index vehicle, the fund reflects the broader balance of these single-stock developments, charging an annual expense ratio of 0.08% across $43.4 billion in net assets. Across longer horizons, XLV stands +16.4% over the past 100 sessions and +20.4% over the past six months, absorbing individual pipeline outcomes within the broader sector trend.